Colon Neoadjuvant FOLFOXIRI Study

NCT01941641 | Active Not Recruiting Phase 2

• 1 other identifier: COL021
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Objective tumour response rate to FOLFOXIRI to pre-operative therapy.

Conditions

Rectal Cancer

Outcome Measures

Primary Outcomes (1)

• Objective tumour response rate

  2 years

Secondary Outcomes (11)

• Tumour regression grade

  2 years

• pathologic complete response

  2 years

• Rate of circumferential resection margin (CRM) clearance

  2 years

• Rate of tumour downstaging

  2 years

• Number of Participants with Adverse Events

  2 years

Study Arms (1)

neoadjuvant FOLFOXIRI

EXPERIMENTAL

Drug: neoadjuvant FOLFOXIRI; Drug: Capecitabine

Interventions

neoadjuvant FOLFOXIRI DRUG

neoadjuvant FOLFOXIRI

Capecitabine DRUG

neoadjuvant FOLFOXIRI

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \>= 18 years of either sex.
• ECOG performance status 0-1
• Measurable disease by RECIST 1.1 criteria.
• Histologically confirmed rectal adenocarcinoma (defined as either mid- or low rectal cancer that is located within 12 cm from the anal verge OR below the peritoneal reflection) that is previously untreated.
• 'High risk' rectal cancer, or rectal cancers that are considered marginally operable where there is a significant risk of positive surgical margin:
• T3 (low-lying tumour at or below the levators) or T4, or
• Tumour infiltrating perirectal fat, or
• Any T-stage (T1-4) and node-positive tumour (invading surrounding structures or peritoneum)
• Adequate bone marrow, renal and hepatic function as defined by: absolute neutrophil count \>= 1.5 x 109/L, hemoglobin \>= 9 g/L, platelets \>= 100 x 109/L, calculated creatinine clearance \>= 55 ml/min, total bilirubin =\<1.5 x the upper limit of normal, alanine aminotransferase (ALT) =\<2.5 upper limit of normal.

You may not qualify if:

• Known distant metastasis, even if the metastasis has been resected.
• History of another invasive malignancy within the last 5 years, except for treated basal cell carcinoma of the skin, cervical intraepithelial neoplasia, or non-invasive DCIS of the breast.
• Upper rectal cancer that is located above the peritoneal reflection.
• Primary tumour associated with any one of the following features:
• Frank intestinal obstruction, or
• Endoscope unable to pass through the tumour's lumen plus worsening local obstructive symptoms. Note: Patients with such features should be assessed by the surgical team regarding stomal bypass prior to study enrolment. Such patients can still be considered for study enrolment after undergoing stomal bypass.
• Known hypersensitivity reaction to the study drugs (i.e. fluoropyrimidine, irinotecan, oxaliplatin)
• Known peripheral neuropathy of grade 2 or more in severity.
• Patients who have received an experimental anticancer therapy within the last 28 days.
• Previous pelvic radiotherapy. Previous oxaliplatin or irinotecan for the treatment of colon or rectal cancer
• Patient with hip prosthesis
• Major surgery within the last 28 days. Exception: Any patient who underwent stomal bypass for obstructing primary tumour within the last 14 days are still eligible, as long as the patient has sufficiently recovered from the surgery at the investigator's discretion.

Sponsors & Collaborators

• Chinese University of Hong Kong: lead

Study Sites (1)

Department of Clinical Oncology

Hong Kong, Hong Kong

Location

MeSH Terms

Conditions

Rectal Neoplasms

Interventions

Capecitabine

Condition Hierarchy (Ancestors)

Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Intestinal Diseases; Rectal Diseases

Intervention Hierarchy (Ancestors)

Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Fluorouracil; Uracil; Pyrimidinones; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides

Study Officials

• Brigette MA, MD, FRCP

  Chinese University of Hong Kong

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Comprehensive Cancer Trials Unit

Study Record Dates

• First Submitted: September 3, 2013
• First Posted: September 13, 2013
• Study Start: October 9, 2013
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2027
• Last Updated: November 17, 2025

Record last verified: 2025-11

Locations

HK (1)